Navigation Links
The Novel Oral Anticoagulants Will Continue to Drive Growth in the Atrial Fibrillation Drug Market
Date:12/19/2013

BURLINGTON, Mass., Dec. 19, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the atrial fibrillation drug market will experience continued growth through the rest of the decade, increasing from $3.4 billion in 2012 to $8.6 billion in 2020 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. However, generic entry of Boehringer Ingelheim's Pradaxa and Bayer/Janssen's Xarelto will result in contraction of the atrial fibrillation market in the latter part of the 2012 to 2022 forecast period, with the market contracting to $8.1 billion in 2022.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO)

The Pharmacor advisory service entitled Atrial Fibrillation, which will be published in the days ahead, finds that the novel oral anticoagulants developed for the prevention of stroke in atrial fibrillation patients will continue to drive market growth, accounting for approximately 70 percent market share in 2022. Despite a slow start following its 2013 launch, Bristol-Myers Squibb/Pfizer's Eliquis is expected to be the sales-leading anticoagulant and will garner more than $2.7 billion in 2022. The use of the new anticoagulants will result in a steep decline in sales of warfarin (Bristol-Myers Squibb's Coumadin, Eisai's Warfarin, generics) and other currently available vitamin K antagonists. The anticipated launch of Armetheon's tecarfarin as an anticoagulant therapy for atrial fibrillation patients with mechanical heart valves in the United States will see vitamin K antagonists remain a notable presence in the at
'/>"/>

SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Mylan Announces Acquisition of Rights to Novel LAMA Respiratory Compound from Pfizer
2. BioLineRx Enters Clinic with Novel Treatment for Celiac Disease
3. ARGX-110, a Novel Anti-CD70 Antibody, Meets Translational Development Goals in Dose Escalation Part of Phase Ib Cancer Study
4. The Market for Non-Small-Cell Lung Cancer (NSCLC) Will Grow to $7 Billion in 2022, Fuelled by the Entry of Twelve Novel Agents
5. The Acute Coronary Syndrome 12-Month Posthospital Market Will Double by 2022, Driven by the Uptake of Novel Lipid Modifying Agents
6. Sutro Biopharma Closes $26 Million Financing, Expands Development of Novel Immuno-Oncology Products
7. High Cost of Biologics and Novel Oral Agents to Treat Immune Diseases Limits Patient Access
8. Opportunity Exists in the U.S. for Novel Agents in Crohns Disease and Ulcerative Colitis, Owing to Discontinued Use of Leading Anti-TNF Agents Driven by Efficacy Failures
9. Synthetic Biologics Enters into License with Cedars-Sinai Medical Center to Develop Novel Anti-infective Approaches for Irritable Bowel Syndrome (IBS), Obesity and Diabetes
10. Bavarian Nordic, the international novel cancer and infectious disease vaccines focused biotech, now covered by Edison.
11. FLAG Therapeutics and Duquesne University Announce Exclusive Worldwide Licensing Agreement for Novel, Dual-action Targeted Oncology Compounds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... -- CytRx Corporation (NASDAQ: CYTR ), a ... that data regarding the Company,s Phase 2b global clinical ... tissue sarcoma (STS) will be presented in a moderated ... (CTOS) Annual Meeting which is being held October 15-18, ... the longer than expected survival of patients in the ...
(Date:10/16/2014)...  One of California,s most ... the Patient Advocate — this week recognized Kaiser Permanente,s ... state for the seventh consecutive year. The ... and Kaiser Permanente Southern California are the only health ... a four-star rating — the highest possible — for ...
(Date:10/16/2014)... YORK , Oct. 16, 2014 Curtis ... organizer is under 3 weeks away from hosting their co-located ... and Oral Drug Formulation Innovations Summit taking ... San Diego, CA. November,s ... development organizations in streamlining the bioequivalence testing process, as ...
Breaking Medicine Technology:CytRx to Present Data from Global Phase 2b Clinical Trial of Aldoxorubicin in First-Line Soft Tissue Sarcoma at 2014 CTOS Annual Meeting 2CytRx to Present Data from Global Phase 2b Clinical Trial of Aldoxorubicin in First-Line Soft Tissue Sarcoma at 2014 CTOS Annual Meeting 3CytRx to Present Data from Global Phase 2b Clinical Trial of Aldoxorubicin in First-Line Soft Tissue Sarcoma at 2014 CTOS Annual Meeting 4CytRx to Present Data from Global Phase 2b Clinical Trial of Aldoxorubicin in First-Line Soft Tissue Sarcoma at 2014 CTOS Annual Meeting 5CytRx to Present Data from Global Phase 2b Clinical Trial of Aldoxorubicin in First-Line Soft Tissue Sarcoma at 2014 CTOS Annual Meeting 6Kaiser Permanente's California Health Plans Rated Highest for Quality for Seventh Consecutive Year 2Kaiser Permanente's California Health Plans Rated Highest for Quality for Seventh Consecutive Year 3Simplifying the Bioequivalence Testing Process and Optimizing Oral Formulation Development via Unifying the Global Life Science Community this November in San Diego 2
... July 14 ERT (Nasdaq: ERES ) announced today that ... August 9, 2010 , after the market closes. After the release, the Company ... , , , ... participants should dial 1-800-860-2442 when calling within the United States or ...
... , HONOLULU , July 14 EnVivo ... on Alzheimer,s Disease (ICAD) results from its proprietary gamma-secretase modulator ... reduced amyloid plaque buildup which is believed to be a ... inflammation associated with Alzheimer,s disease. , ...
Cached Medicine Technology:ERT to Announce Second Quarter 2010 Results on August 9, 2010 2EnVivo Pharmaceuticals Announces Significant Results from GSM Transgenic Mouse Model for Alzheimer's Disease 2
(Date:10/20/2014)... Rockynol Retirement Community broke ground ... The $11 million project will include the latest in ... with full-service restaurant style dining. , “We are excited ... Assisted Living apartments,” said Kara Hanzie, Rockynol Executive Director ... of care and this investment is proof of our ...
(Date:10/20/2014)... 20, 2014 Based on a ... only imaging assays capable of determining DNA sequence, ... With these three dimensions of high-resolution data, dGH ... the widest range of disease-causing genetic rearrangements, including ... other genomic tools, including today’s advanced sequencing technologies. ...
(Date:10/20/2014)... Final Cut Pro X Plugin developers from ... theme for FCPX filmmakers . , “Fun, cool, and ... Citrus theme” Says Christina Austin, CEO of Pixel Film Studios. ... , Citrus comes with all the tools needed for a ... transitions for added style, a title screen for an introduction, ...
(Date:10/20/2014)... hard to imagine what it’s like to live without shoes, ... it’s a reality. And while new shoes are considered a ... barefoot on rocky terrain or sewage-lined streets just to collect ... , Buckner International's Shoes for Orphan Souls project ... encourage support for Air1 and while also providing new shoes ...
(Date:10/20/2014)... Texas (PRWEB) October 20, 2014 Houston ... to present the key elements of his innovative ... professor to plastic surgery residents and faculty at ... , where he, too, was once a medical student. ... the largest private cosmetic plastic surgery practices in Texas, ...
Breaking Medicine News(10 mins):Health News:Rockynol Retirement Community Expands Assisted Living Center 2Health News:KromaTiD Launches Genome Screening and Discovery Services 2Health News:KromaTiD Launches Genome Screening and Discovery Services 3Health News:Today Pixel Film Studios Announced the Release of the Citrus theme for Final Cut Pro X 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 3Health News:Plastic Surgeon Patronella Presents Artistically-Inspired Tummy Tuck Method to Future Generation of Plastic Surgeons in Texas 2
... obstacles, research shows , TUESDAY, Feb. 16 (HealthDay News) ... seek treatment for post-traumatic stress disorder, researchers say. , ... Iraq and Afghanistan wars received diagnoses of post-traumatic stress ... the recommended treatment of 10 to 12 weekly sessions ...
... Gets ... ... 16, 2010 -- BusinessCard2 ™, a web-based personal brand management, marketing, and social ... The competition was established to recognize great work in open/social business and organizational design, ...
... confirm that combination hormone therapy increases the risk of heart ... toward an increased risk of heart disease during the first ... within 10 years of menopause, and a more marked elevation ... 10 years after menopause. Analyses indicate that overall a ...
... Survey found most people thought they were fine, while their ... rising rates of obesity and diabetes, a new survey has ... just fine - it,s everyone else who has the problem. ... people,s health "was going in the wrong direction." In contrast, ...
... ... recorded in global sequence databases is growing exponentially, and legal professionals and scientists doing ... discover IP sequence information across these databases. The free seminar includes lunch and roundtable ... (Vocus) ...
... ... contracted with Atlanta-based Premier Anesthesia to manage the anesthesia services for its hospital and ... ... east Texas, has contracted with Atlanta-based Premier Anesthesia to manage the anesthesia services for ...
Cached Medicine News:Health News:BusinessCard2 Wins Social Business Innovation Award 2Health News:BusinessCard2 Wins Social Business Innovation Award 3Health News:WHI data confirm short-term heart disease risks of combination menopausal hormone therapy 2Health News:WHI data confirm short-term heart disease risks of combination menopausal hormone therapy 3Health News:WHI data confirm short-term heart disease risks of combination menopausal hormone therapy 4Health News:Most Americans Think It's Others Who Are Unhealthy 2Health News:Most Americans Think It's Others Who Are Unhealthy 3Health News:GenomeQuest Hosts Seminar Focused On Web-based Searching for Patent Information Across Global Sequence Databases 2Health News:Premier Anesthesia Forges New Partnership with Texas Hospital 2
... fixation. Completely resorbable, it presented surgeons with ... the most thoroughly proven product of its ... with system enhancements that make it even ... system means that application of this proven ...
... The intra-operative MR system ... intra-operative tool for radiologists ... goal of the system ... valuable adjunct to standard ...
... ultrasound A-scan Sonomed-315 is intended for visualization ... detection of midline shifts in the brain, ... and easy to use, the Sonomed-315 offers ... A-scanning mode allows to identify the anatomic ...
... With Plasmaseal's Proteus device the two steps ... is injected into Proteus' single use disposable ... base unit. The operator touches a button, ... is separated by centrifugation. Then the integral ...
Medicine Products: